Loading…
← CockpitCompetitor Analysis › PHM.MC Pharma Mar SAOpen in the cockpit ↗

Pharma Mar SAPHM.MCCompetitor analysis, valuation and peers

Spain · EUR·Health Care›Pharmaceuticals: Other

Spanish biotech developing marine-derived oncology drugs, including approved treatments Yondelis and Zepzelca.

≈ A smaller, marine-natural-products oncology biotechMomentum laggard 4
Mkt cap
$1.21B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$3.12M
20-day average traded
Fwd P/E
41.4×
forward earnings
ROIC−WACC
+17.2 pp
WACC 8.3%
Hurdle
+14 pp
Req g minus delivered
Next earnings
103 days
1 Mar 2027
Close · EUR€62.05
1D-3.4%
1W-10.5%
1M-10.4%
3M-25.5%
6M-38.4%
YTD-17.2%
1Y-18.0%
ATR %3.4%
52w lowhigh41.0% off high

What Pharma Mar does

Spanish biotech developing marine-derived oncology drugs, including approved treatments Yondelis and Zepzelca.

Sells Yondelis itself through its own oncology sales force in Europe, while for Zepzelca it relies on partner Jazz Pharmaceuticals in the US, so much of its income is licence fees, milestone payments and supply to partners rather than its own selling. It also holds a separate RNA-interference research business.

In one line: A smaller, marine-natural-products oncology biotech.

Products and services

  • Yondelis (trabectedin)
  • Zepzelca/lurbinectedin
  • Oncology pipeline candidates

Customers

  • Oncologists
  • Hospitals
  • Licensing partners (e.g., Jazz Pharmaceuticals)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Oncology drug discovery +…

What could go right

  • Zepzelca sales growth/label expansion
  • New oncology drug approvals

What could go wrong

  • Clinical trial failure risk
  • Revenue concentration in a few drugs

Moat: narrow (IP / patents, process know-how). Proprietary marine-compound discovery platform and patents on approved oncology drugs.

Headquarters: Madrid, Spain · Founded: 1986

Named competitors

Pharma Mar at a glance

Size Pharma Mar (PHM.MC) is a Spain Health Care company (Pharmaceuticals: Other) with a market value of $1.21B, the 64th largest of 93 Spain companies the cockpit tracks. Shares closed at €62.05 on 18 Nov 2026.

Performance Over six months the shares fell 38.4%, against -9.8% for the median peer and +5.3% for the Spain market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 32.4% over the last twelve months (peer median +4.6%); the operating margin is 18.7% (peer median 14.0%).

Valuation It trades at 41.4× forward earnings against a peer median of 16.2× (4th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 17.2 points above its cost of capital (8.3% WACC).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 90PHM.MC 61
Six months, rebased to 100: Pharma Mar against the median of its 20 peers (local-currency closes).

Pharma Mar financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€237M€221M€175M€158M€196M
Revenue growth—+27%+11%-19%—
Gross profit€213M€201M€160M€145M€179M
EBITDA€52.7M€48.3M€9.34M€406,000€48.2M
Net income€68.4M€75.0M€26.1M€1.14M€49.4M
Free cash flow€44.4M€46.7M-€8.99M-€29.4M€29.5M
Capital expenditure€8.39M€9.38M€15.5M€16.0M€8.85M
Total debt€70.1M€49.4M€50.9M€43.4M€42.4M

Quarterly statements and history in the cockpit →

Pharma Mar competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%BIOG-BCRON64722142JWEL0022750719SUDEEPPHRMAPN600216002219PHN30036304606032622877300791600488PHM.MC6-month return →1-month return →
Up and to the right = strong over both horizons. Pharma Mar is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×BIOG-BCRON64722142JWEL0022750719SUDEEPPHRMAPN00221904606032622877300791PHM.MCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pharma Mar is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%BIOG-BCRON64722142JWEL0022750719APN600216PHN603262600056300791600488PHM.MCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Pharma Mar is the large dot.

Pharma Mar competitors and peer comparison

Head to head with its named competitors (PHM.MC vs JAZZ vs 6446.TW vs IPN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Pharma Mar PHM.MC$1.21B-38%+32%19%41.4×10.6%
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%9.3×-2.8%
PharmaEssentia 6446.TW$15.0B+67%+78%40%31.9×23.7%
Ipsen IPN.PA$14.8B+1%+14%30%10.8×-6.7%

How Pharma Mar compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pharma Mar against its 20 peers (data as of 18 Nov 2026)
MeasurePHM.MCPeer medianRank in peer set
1-month return-10.4%-3.5%5th lowest of 21
6-month return-38.4%-9.8%2nd lowest of 21
Distance from 52-week high-41.0%-31.7%6th lowest of 21
Revenue growth (TTM)+32.4%+4.6%4th highest of 21
Operating margin18.7%14.0%9th highest of 21
Forward P/E41.4×16.2×4th most expensive of 17
Growth the price implies (Req g, 7 yrs)10.6%2.8%7th most demanding of 17
Growth delivered (Del g)-3.9%+14.3%lowest of 17
Hurdle (Req g minus delivered)+14.4 pp-10.5 ppmost demanding of 17
ROIC minus cost of capital+17.2 pp+2.5 pp6th highest of 21
EV / EBITDA18.9×17.4×5th most expensive of 10
Net debt / EBITDA-2.0×-0.7×5th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Shandong Xinhua Pharmaceutical 0719.HKHong Kong$1.03B-19%-1%4%6.2×-2.1%+7.1%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%

Questions

Who are Pharma Mar's main competitors?
Named competitors: Jazz Pharmaceuticals (JAZZ), PharmaEssentia (6446.TW), Ipsen (IPN.PA), Servier (private) (private or unlisted). The cockpit's measured peer set (industry) also includes BioGaia (BIOG-B.ST), Cronos (CRON.TO), Bora Pharmaceuticals (6472.TW), HBM (2142.HK), Jamieson Wellness (JWEL.TO), Guilin Sanjin Pharmaceutical (002275.SZ).
Is Pharma Mar expensive compared with its peers?
On forward p/e it trades at 41.4× against a peer median of 16.2×, 4th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Pharma Mar stock performed?
Over six months to 18 Nov 2026 the shares returned -38.4% against -9.8% for the median peer; over one year -18.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.